Liposomal Amphotericin B–Associated Cardiac Arrest: Case Report and Literature Review. Issue 6 (November 2018)

• Record Type: Journal Article
• Authors: Autry, Marcus Tad; Harrison, Kiya; White, Bryan; Miller, Jamie
• Is Part Of: Infectious diseases in clinical practice. Volume 26:Issue 6(2018:Nov.)
• Publication Date: 2018-11
• Subjects: liposomal amphotericin B -- cardiac arrest -- adverse event; Communicable diseases -- Periodicals; Communicable Diseases -- Periodicals; Communicable diseases; Periodicals; Periodicals; Electronic journals; 616.9
• DOI: 10.1097/IPC.0000000000000647
• Languages: English
• ISSNs: 1056-9103

Abstract

Abstract : Abstract: Liposomal amphotericin B (L-AmB) was developed with the intent to minimize the adverse effects associated with amphotericin B deoxycholate, especially nephrotoxicity. Although there has been a substantial decrease in adverse effects with L-AmB compared with its predecessor, there is a small body of evidence suggesting its association with cardiovascular adverse events. We report a case of L-AmB-associated cardiac arrest in a patient with preexisting cardiac-related disease states. In addition, we review currently available literature regarding cardiac-related adverse events associated with L-AmB. When the Naranjo Adverse Drug Reaction Probability Scale was applied to this case, the probability of association was determined as possible . This case adds to a small but important body of literature regarding L-AmB–associated cardiotoxicity. Moreover, a review of the available literature indicates that providers should be aware of the potential for cardiac adverse events with L-AmB.